The recent growth of Hepatitis C treatment, now has payers considering the HCV category right up there with cancer, rheumatoid arthritis, and multiple sclerosis. Take a look at the recent approval of new hepatitis C treatments in Specialty Pharmacy Times’, Keeping an Eye on Hepatitis C Virus Drug Approvals, available here. (Source: :Lee Goldberg, Specialty Pharmacy Times, 8/20/14).
You are here: Home / Industry News / How Are Payers Controlling Costs With New Hepatitis C Treatments?